Upcoming Roundtables
2026 Biomarker Phenotype Pilot Study — Participant Info Session
ClearMark Health is recruiting 30 participants for our 2026 pilot study evaluating biomarkers implicated in post-viral illness, Long COVID, and related syndromes. Join this session to learn about eligibility, what biomarkers we're studying, how phenotyping works, and how to apply.
Speakers
ClearMark Health Research Team
Study Coordinators
Past Roundtables
2025 Biomarker Pilot Study — Results & Lessons Learned
Review of ClearMark Health's completed Attomarker/University of Exeter protein biomarker pilot study, including community fundraising outcomes and how findings inform 2026 research.
Key takeaways: 1) Community fundraising raised $8,500 for the Attomarker biomarker pilot. 2) Protein-based markers show promise for objectifying symptom severity. 3) Partnership with University of Exe...
Vagustim Study Recap — Neuromodulation & Dysautonomia Outcomes
Summary of the completed Vagustim tragus nerve stimulation study: customized stimulation parameters, biomarker changes, dysautonomia measures, and quality-of-life improvements.
Key takeaways: 1) Community raised $7,227 to fund the Vagustim study. 2) Customized parameters (frequency, pulse width, duty cycle) mattered for outcomes. 3) Dysautonomia and QoL scores showed measura...